CoChat
Sign Up
Cited by 113Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Open access
Veitch, Dallas P., Weiner, Michael W., Miller, Melanie, Aisen, Paul S., Ashford, Miriam A., Beckett, Laurel A., Green, Robert C., Harvey, Danielle +15 more·2024·Alzheimer's & Dementia
DOI 10.1002/alz.13449PMC PMC10841343
Open this paper in CoChat — free account

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.13449

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Predictive signatures derived from ADNI datasets often underperform in community-based cohorts that differ in ancestry, education level, and comorbid conditions.

    “Predictive signatures derived from ADNI datasets often underperform in community-based cohorts that differ in ancestry, education level, and comorbid conditions259.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [259]

    In “Diagnosis and prediction approaches” (page unavailable), the review reports that ADNI-developed MRI classifiers performed less well in external memory-clinic cohorts, and that a score tested in the more diverse ARIC cohort performed differently across racial groups. “Generalizability of ADNI results” (page unavailable) also documents differences in ancestry and education between ADNI and a community-based cohort. The copy does not establish that predictive signatures often underperform specifically in community cohorts because of differences in ancestry, education, and comorbid conditions. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 302

  1. [1]Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimers Dement. 2005; 1: 55‐ 66. 17476317 PMC1864941
  2. [2]Marek K, Jennings D, Lasch S, et al. The Parkinson progression marker initiative (PPMI). Prog Neurobiol. 2011; 95: 629‐ 635. 21930184 PMC9014725
  3. [3]Franzmeier N, Brendel M, Beyer L, et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat Commun. 2022; 13: 18. 35292638 PMC8924216
  4. [4]Cadby G, Giles C, Melton PE, et al. Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nat Commun. 2022; 13: 17. 35668104 PMC9170690
  5. [5]Weiner MW, Harvey D, Landau SM, et al. Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. Alzheimers Dement. 2023; 19:884‐895. PMC10269599 35768339
  6. [6]Mackin RS, Insel PS, Landau S, et al. Late‐Life depression is associated with reduced cortical amyloid burden: findings from the Alzheimer's disease neuroimaging initiative depression project. Biol Psychiatry. 2021; 89: 757‐ 765. 32980132 PMC10165941
  7. [7]Bethlehem RAI, Seidlitz J, White SR, et al. Brain charts for the human lifespan. Nature. 2022; 604: 525‐ 533. 35388223 PMC9021021
  8. [8]Veitch DP, Weiner MW, Aisen PS, et al. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 2019; 15: 106‐ 152. 30321505
  9. [9]Veitch DP, Weiner MW, Aisen PS, et al. Using the Alzheimer's disease neuroimaging initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimers Dement. 2022; 18: 824‐ 857. 34581485 PMC9158456
  10. [11]Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2013; 9: e111‐ e194. 23932184 PMC4108198
  11. [12]Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012; 8: S1‐ 68. 22047634 PMC3329969
  12. [13]Weiner MW, Veitch DP, Aisen PS, et al. Recent publications from the Alzheimer's disease neuroimaging initiative: Reviewing progress toward improved AD clinical trials. Alzheimers Dement. 2017; 13: e1‐ e85. 28342697 PMC6818723
  13. [14]Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement. 2017; 13: 561‐ 571. 27931796 PMC5536850
  14. [16]Jack CR Jr., Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016; 87: 539‐ 547. 27371494 PMC4970664
  15. [17]Yasuno F, Minami H. Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: an in vivo positron emission tomography study. Int J Geriatr Psychiatry. 2021; 36: 1274‐ 1283. 33594726
  16. [18]Meng D, Mohammadi‐Nejad AR, Sotiropoulos SN, Auer DP, Alzheimer's Disease Neuroimaging I. Anticholinergic drugs and forebrain magnetic resonance imaging changes in cognitively normal people and those with mild cognitive impairment. Eur J Neurol. 2022; 29: 1344‐ 1353. 35129272 PMC9304308
  17. [19]Li J, Zheng C, Ge Q, et al. Association between long‐term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using (18) F‐AV‐45 and (18) F‐AV‐1451 PET. J Neurosci Res. 2022; 100: 670‐ 680. 34882830
  18. [20]Stage E, Svaldi D, Sokolow S, et al. Prescribing cholinesterase inhibitors in mild cognitive impairment‐observations from the Alzheimer's disease neuroimaging initiative. Alzheimers Dement (NY). 2021; 7: e12168. PMC8719350 35005201
  19. [21]Deng Z, Jiang J, Wang J, et al. Angiotensin receptor blockers are associated with a lower risk of progression from mild cognitive impairment to dementia. Hypertension (Dallas, Tex: 1979). 2022; 79: 2159‐ 2169. 35766029
  20. [22]Weng J, Zhao G, Weng L, Guan J. Aspirin using was associated with slower cognitive decline in patients with Alzheimer's disease. PLoS One. 2021; 16: e0252969. 34133445 PMC8208559
  21. [23]Pomilio C, Perez NG, Calandri I, et al. Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. Geroscience. 2022; 44: 1791‐ 1805. 35445359 PMC9213579
  22. [24]Bouter Y, Bouter C. Selective serotonin reuptake inhibitor‐treatment does not show beneficial effects on cognition or amyloid burden in cognitively impaired and cognitively normal subjects. Front Aging Neurosci. 2022; 14: 883256. 35813957 PMC9260503
  23. [25]van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2022; 388: 9‐ 21. 36449413
  24. [26]Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long‐term health outcomes of lecanemab in patients with early Alzheimer's disease using simulation modeling. Neurolo Ther. 2022; 11: 863‐ 880. PMC9095799 35469060
  25. [27]Cullen N, Janelidze S, Palmqvist S, et al. Association of CSF Abeta38 levels with risk of Alzheimer disease‐related decline. Neurology. 2022; 98: e958‐ e967. 34937781 PMC8901176
  26. [29]Josephs KA, Weigand SD, Whitwell JL. Characterizing Amyloid‐positive individuals with normal tau PET levels after 5 years: an ADNI study. Neurology. 2022; 98: e2282‐ e2292. 35314506 PMC9162162
  27. [30]Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015; 11: 1‐ 15. e4. 25443857 PMC4300247
  28. [31]Matthews DC, Lukic AS, Andrews RD, et al. Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. Alzheimers Dement (N Y). 2022; 8: e12325. 35846158 PMC9270637
  29. [32]Jutten RJ, Sikkes SAM, Van der Flier WM, Scheltens P, Visser PJ, Tijms BM. Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity. Neurology. 2021; 96: e2673‐ e2684. 34550903 PMC8205463
  30. [33]Giraldo DL, Sijbers J, Romero E, Initiative AsDN. Quantification of cognitive impairment to characterize heterogeneity of patients at risk of developing Alzheimer's disease dementia. Alzheimers Dement. 2021; 13: e12237. PMC8439141 34541290
  31. [34]Berres M, Monsch AU, Spiegel R. Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets. Alzheimers Res Ther. 2021; 13: 97. 33962665 PMC8106156
  32. [35]Kiselica AM, Benge JF, Alzheimer's Disease neuroimaging I. neuropsychological equivalence of the clinical diagnosis of mild cognitive impairment in the national Alzheimer's coordinating center uniform data set and Alzheimer's disease neuroimaging initiative. Dement Geriatr Cogn Disord. 2021; 50: 231‐ 236. 34186536 PMC8819646
  33. [36]Abi Nader C, Ayache N, Frisoni GB, Robert P, Lorenzi M, Alzheimer's disease neuroimaging I. Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data. Brain Commun. 2021; 3: fcab091. 34085040 PMC8168944
  34. [37]Clément AN, Ribaldi F, Frisoni GB, et al. SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer's disease. Neurobiol Aging. 2022; 113: 73‐ 83. 35320737
  35. [39]Bullich S, Roe‐Vellve N, Marquie M, et al. Early detection of amyloid load using (18)F‐florbetaben PET. Alzheimers Res Ther. 2021; 13: 67. 33773598 PMC8005243
  36. [40]Pegueroles J, Montal V, Bejanin A, et al. AMYQ: An index to standardize quantitative amyloid load across PET tracers. Alzheimers Dement. 2021; 17: 1499‐ 1508. 33797846 PMC8519100
  37. [41]Weigand AJ, Maass A, Eglit GL, Bondi MW. What's the cut‐point?: a systematic investigation of tau PET thresholding methods. Alzheimers Res Ther. 2022; 14: 49. 35382866 PMC8985353
  38. [42]Dumurgier J, Sabia S, Zetterberg H, et al. Pragmatic, data‐driven method to determine cutoffs for CSF biomarkers of Alzheimer disease based on validation against PET imaging. Neurology. 2022; 99: e669‐ e678. 35970577 PMC9484605
  39. [43]Shishegar R, Cox T, Rolls D, et al. Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. Sci Rep. 2021; 11: 23788. 34893624 PMC8664816
  40. [44]Hampton OL, Mukherjee S, Properzi MJ, et al. Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies. Neuropsychology. 2023; 37: 436‐ 449. 35862098 PMC9859944
  41. [45]Salimi Y, Domingo‐Fernández D, Bobis‐Álvarez C, Hofmann‐Apitius M, Birkenbihl C. ADataViewer: exploring semantically harmonized Alzheimer's disease cohort datasets. Alzheimers Res Ther. 2022; 14: 69. 35598021 PMC9123725
  42. [46]Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood‐based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022; 21: 66‐ 77. 34838239
  43. [47]Balogun WG, Zetterberg H, Blennow K, Karikari TK. Plasma biomarkers for neurodegenerative disorders: ready for prime time? Curr Opin Psychiatry. 2023; 36: 112‐ 118. 36607770 PMC9872855
  44. [48]Zicha S, Bateman RJ, Shaw LM, et al. Comparative analytical performance of multiple plasma Abeta42 and Abeta40 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimers Dement. 2023; 19:956‐966. PMC10518222 35820077
  45. [49]Udeh‐Momoh C, Zheng B, Sandebring‐Matton A, et al. Blood derived amyloid biomarkers for Alzheimer's disease prevention. J Prev Alzheimers Dis. 2022; 9: 12‐ 21. 35098969
  46. [50]Li Y, Schindler SE, Bollinger JG, et al. Validation of Plasma Amyloid‐beta 42/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022; 98: E688‐ E699. 34906975 PMC8865895
  47. [51]Chen SD, Huang YY, Shen XN, et al. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. Transl Psychiatry. 2021; 11: 356. 34120152 PMC8197760
  48. [52]Wang YL, Chen J, Du ZL, et al. Plasma P‐tau181 level predicts neurodegeneration and progression to Alzheimer's dementia: a longitudinal study. Front Neurol. 2021; 12: 695696. 34557143 PMC8452983
  49. [53]Lussier FZ, Benedet AL, Therriault J, et al. Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid‐positive individuals. Brain Commun. 2021; 3: fcab073. 33959711 PMC8088291
  50. [54]Shen XN, Huang YY, Chen SD, et al. Plasma phosphorylated‐tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. Transl Psychiatry. 2021; 11: 585. 34775468 PMC8590691
  51. [55]Tissot C, A LB, Therriault J, et al. Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. Alzheimers Res Ther. 2021; 13: 69. 33781319 PMC8008680
  52. [57]Tropea TF, Waligorska T, Xie SX, et al. Plasma phosphorylated tau181 predicts cognitive and functional decline. Ann Clin Transl Neurol. 2023; 10: 18‐ 31. 36518085 PMC9852389
  53. [58]Grothe MJ, Moscoso A, Ashton NJ, et al. Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy. Neurology. 2021; 97: e1229‐ e1242. 34266917 PMC8480485
  54. [59]Zettergren A, Lord J, Ashton NJ, et al. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's disease neuroimaging initiative. Alzheimers Res Ther. 2021; 13: 17. 33419453 PMC7792087
  55. [60]Hazan J, Alston D, Fox NC, Howard R. Practical application of Alzheimer's disease neuroimaging initiative plasma P‐tau181 reference data to support diagnosis of Alzheimer's disease. Int J Geriatr Psychiatry. 2022; 37. 34997780
  56. [61]Palmqvist S, Tideman P, Cullen N, Alzheimer's Disease Neuroimaging I, et al. Prediction of future Alzheimer's disease dementia using plasma phospho‐tau combined with other accessible measures. Nat Med. 2021; 27: 1034‐ 1042. 34031605
  57. [63]Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho‐tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020; 324: 772‐ 781. 32722745 PMC7388060
  58. [64]Janelidze S, Berron D, Smith R, et al. Associations of plasma phospho‐Tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021; 78: 149‐ 156. 33165506 PMC7653537
  59. [65]Marks JD, Syrjanen JA, Graff‐Radford J, et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther. 2021; 13: 199. 34906229 PMC8672619
  60. [66]Bangen KJ, Thomas KR, Weigand AJ, et al. Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI. Alzheimers Dement. 2021; 17: 1756‐ 1762. 33860596 PMC8517034
  61. [67]Qu Y, Tan CC, Shen XN, et al. Association of plasma neurofilament light with small vessel disease burden in nondemented elderly: A longitudinal study. Stroke. 2021; 52: 896‐ 904. 33517704
  62. [68]Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 2021; 78: 396‐ 406. 33427873 PMC7802009
  63. [70]Anggono V, Tsai L‐H, Götz J. Glutamate Receptors in Alzheimer's Disease: Mechanisms and Therapies. Hindawi; 2016: 8256196 PMC4884857 27293907
  64. [71]Tian C, Stewart T, Hong Z, et al. Blood extracellular vesicles carrying synaptic function‐and brain‐related proteins as potential biomarkers for Alzheimer's disease. Alzheimers Dement. 2023; 19:909‐923. PMC9806186 35779041
  65. [72]Silva CT, Young JI, Zhang L, et al. Cross‐tissue analysis of blood and brain epigenome‐wide association studies in Alzheimer's disease. Nat Commun. 2022; 13: 4852. 35982059 PMC9388493
  66. [73]Fouladi S, Safaei AA, Arshad NI, Ebadi MJ, Ahmadian A. The use of artificial neural networks to diagnose Alzheimer's disease from brain images. Multimed Tools Appl. 2022; 81: 37681‐ 37721.
  67. [74]Chen YR, Qian XL, Zhang YY, et al. Prediction models for conversion from mild cognitive impairment to Alzheimer's disease: a systematic review and meta‐analysis. Front Aging Neurosci. 2022; 14: 11. PMC9049273 35493941
  68. [75]Rowe TW, Katzourou IK, Stevenson‐Hoare JO, Bracher‐Smith MR, Ivanov DK, Escott‐Price V. Machine learning for the life‐time risk prediction of Alzheimer's disease: a systematic review. Brain Commun. 2021; 3: 17. PMC8598986 34805994
  69. [78]Dansson HV, Stempfle L, Egilsdóttir H, et al. Predicting progression and cognitive decline in amyloid‐positive patients with Alzheimer's disease. Alzheimers Res Ther. 2021; 13: 151. 34488882 PMC8422748
  70. [79]Pfeil J, Hoenig MC, Doering E, et al. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. Neurobiol Aging. 2021; 106: 119‐ 129. 34284259 PMC8461082
  71. [80]Kim HJ, Oh JS, Lim JS, et al. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid‐negative amnestic mild cognitive impairment. Alzheimers Res Ther. 2022; 14: 93. 35821150 PMC9277922
  72. [81]Farrell ME, Jiang S, Schultz AP, et al. Defining the lowest threshold for Amyloid‐PET to predict future cognitive decline and amyloid accumulation. Neurology. 2021; 96: e619‐ e631. 33199430 PMC7905788
  73. [82]Hu WT, Ozturk T, Kollhoff A, Wharton W, Christina Howell J. Higher CSF sTNFR1‐related proteins associate with better prognosis in very early Alzheimer's disease. Nat Commun. 2021; 12: 4001. 34183654 PMC8238986
  74. [83]Biel D, Brendel M, Rubinski A, et al. Tau‐PET and in vivo Braak‐staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther. 2021; 13: 137. 34384484 PMC8361801
  75. [84]Ossenkoppele R, Reimand J, Smith R, et al. Tau PET correlates with different Alzheimer's disease‐related features compared to CSF and plasma P‐tau biomarkers. EMBO Mol Med. 2021; 13: e14398. 34254442 PMC8350902
  76. [85]Therriault J, Vermeiren M, Servaes S, et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 2023; 80: 188‐ 199. 36508198 PMC9856704
  77. [86]Guo Y, Huang YY, Shen XN, et al. Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET. Alzheimers Res Ther. 2021; 13: 93. 33947453 PMC8094494
  78. [87]Provost K, Iaccarino L, Soleimani‐Meigooni DN, et al. Comparing ATN‐T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. Eur J Nucl Med Mol Imaging. 2021; 48: 2259‐ 2271. 33398408 PMC8178158
  79. [88]Bron EE, Klein S, Papma JM, et al. Cross‐cohort generalizability of deep and conventional machine learning for MRI‐based diagnosis and prediction of Alzheimer's disease. NeuroImage Clin. 2021; 31: 102712. 34118592 PMC8203808
  80. [89]Pelkmans W, Vromen EM, Dicks E, et al. Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. Brain Commun. 2022; 4: fcac026. 35310828 PMC8924646
  81. [90]Venkatraghavan V, Vinke EJ, Bron EE, et al. Progression along data‐driven disease timelines is predictive of Alzheimer's disease in a population‐based cohort. Neuroimage. 2021; 238: 118233. 34091030
  82. [91]Blazhenets G, Ma Y, Sorensen A, et al. Principal components analysis of brain metabolism predicts development of Alzheimer dementia. J Nucl Med. 2019; 60: 837‐ 843. 30389825
  83. [92]Blazhenets G, Frings L, Ma Y, et al. Validation of the Alzheimer disease dementia conversion‐related pattern as an ATN Biomarker of neurodegeneration. Neurology. 2021; 96: e1358‐ e1368. 33408150 PMC8589294
  84. [93]Yang F, Jiang J, Alberts I, et al. Combining PET with MRI to improve predictions of progression from mild cognitive impairment to Alzheimer's disease: an exploratory radiomic analysis study. Ann Transl Med. 2022; 10: 513. 35928737 PMC9347042
  85. [94]Li Y, Haber A, Preuss C, et al. Transfer learning‐trained convolutional neural networks identify novel MRI biomarkers of Alzheimer's disease progression. Alzheimers Dement (Amst). 2021; 13: e12140. 34027015 PMC8120261
  86. [95]Fletcher E, Gavett B, Crane P, et al. A robust brain signature region approach for episodic memory performance in older adults. Brain. 2021; 144: 1089‐ 1102. 33895818 PMC8105039
  87. [96]Casanova R, Hsu FC, Sink KM, et al. Alzheimer's disease risk assessment using large‐scale machine learning methods. PLoS One. 2013; 8: e77949. 24250789 PMC3826736
  88. [97]Casanova R, Hsu FC, Barnard RT, et al. Comparing data‐driven and hypothesis‐driven MRI‐based predictors of cognitive impairment in individuals from the atherosclerosis risk in communities (ARIC) study. Alzheimers Dement. 2022; 18: 561‐ 571. 34310039 PMC8789939
  89. [98]Pinaya WHL, Scarpazza C, Garcia‐Dias R, et al. Using normative modelling to detect disease progression in mild cognitive impairment and Alzheimer's disease in a cross‐sectional multi‐cohort study. Sci Rep. 2021; 11: 13. 34344910 PMC8333350
  90. [99]Song YH, Yi JY, Noh Y, et al. On the reliability of deep learning‐based classification for Alzheimer's disease: multi‐cohorts, multi‐vendors, multi‐protocols, and head‐to‐head validation. Front Neurosci. 2022; 16: 851871. 36161156 PMC9490270
  91. [100]Lu B, Li HX, Chang ZK, et al. A practical Alzheimer's disease classifier via brain imaging‐based deep learning on 85,721 samples. J Big Data. 2022; 9: 22.35223368
  92. [102]Lin RR, Xue YY, Li XY, et al. Optimal combinations of AT(N) biomarkers to determine longitudinal cognition in the Alzheimer's disease. Front Aging Neurosci. 2021; 13: 14. PMC8377373 34421579
  93. [103]Visser PJ, Reus LM, Gobom J, et al. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Mol Neurodegener. 2022; 17: 27. 35346299 PMC8962234
  94. [104]Llano DA, Devanarayan P, Devanarayan V, Alzheimer's disease neuroimaging I. CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework. Neurobiol Aging. 2023; 121: 15‐ 27. 36368195
  95. [105]Ezzati A, Abdulkadir A, Jack CR Jr., et al. Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia. Alzheimers Dement. 2021; 17: 1855‐ 1867. 34870371 PMC8842842
  96. [106]Vromen EM, de Boer SCM, Teunissen CE, et al. Biomarker A+T‐: is this Alzheimer's disease or not? A combined CSF and pathology study. Brain. 2023; 146: 1166‐ 1174. 35511164 PMC9976983
  97. [107]Brum WS, de Bastiani MA, Bieger A, et al. A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. Alzheimers Dement. 2022; 8: e12270. PMC8918110 35310530
  98. [108]Smith R, Cullen NC, Pichet Binette A, et al. Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement. 2023; 19:2497‐2507. PMC10264552 36516028
  99. [109]O'Shea DM, Thomas KR, Asken B, et al. Adding cognition to AT(N) models improves prediction of cognitive and functional decline. Alzheimers Dement. 2021; 13: e12174. PMC8012408 33816757
  100. [110]Morrison C, Dadar M, Shafiee N, Villeneuve S, Louis Collins D, for Alzheimer's disease neuroimaging I. Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline. NeuroImage Clinical. 2022; 33: 102923. 34959049 PMC8718726
  101. [111]Howell T, Neuhaus J, Glymour MM, Weiner MW, Nosheny RL. Validity of online versus in‐clinic self‐reported everyday cognition scale. J Prev Alzheimers Dis. 2022; 9: 269‐ 276. 35543000 PMC9881822
  102. [112]Bock JR, Hara J, Fortier D, Lee MD, Petersen RC, Shankle WR. Application of digital cognitive biomarkers for Alzheimer's disease: identifying cognitive process changes and impending cognitive decline. J Prev Alzheimers Dis. 2021; 8: 123‐ 126. 33569557
  103. [113]Edgar CJ, Siemers E, Maruff P, et al. Pilot evaluation of the unsupervised, at‐home cogstate brief battery in ADNI‐2. J Alzheimers Dis. 2021; 83: 915‐ 925. 34366337 PMC8543269
  104. [114]Pyun JM, Park YH, Lee KJ, et al. Predictability of polygenic risk score for progression to dementia and its interaction with APOE epsilon4 in mild cognitive impairment. Transl Neurodegener. 2021; 10: 32. 34465370 PMC8406896
  105. [115]Liu H, Lutz M, Luo S, Alzheimer's Disease Neuroimaging I. Association between polygenic risk score and the progression from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis. 2021; 84: 1323‐ 1335. 34657885 PMC8957404
  106. [116]Yang J, Wang Z, Fu Y, et al. Prediction value of the genetic risk of type 2 diabetes on the amnestic mild cognitive impairment conversion to Alzheimer's disease. Front Aging Neurosci. 2022; 14: 964463. 36185474 PMC9521369
  107. [117]Leonenko G, Baker E, Stevenson‐Hoare J, et al. Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores. Nat Commun. 2021; 12: 10. 34301930 PMC8302739
  108. [118]Iturria‐Medina Y, Carbonell F, Assadi A, et al. Integrating molecular, histopathological, neuroimaging and clinical neuroscience data with NeuroPM‐box. Commun Biol. 2021; 4: 20. 34021244 PMC8140107
  109. [119]Hao W, Lenhart S, Petrella JR. Optimal anti‐amyloid‐beta therapy for Alzheimer's disease via a personalized mathematical model. PLoS Comput Biol. 2022; 18: e1010481. 36054214 PMC9477429
  110. [120]Wang M, Sajobi TT, Ismail Z, et al. A pragmatic dementia risk score for patients with mild cognitive impairment in a memory clinic population: Development and validation of a dementia risk score using routinely collected data. Alzheimers Dement (N Y). 2022; 8: e12301. 35592692 PMC9092734
  111. [121]Koval I, Bone A, Louis M, et al. AD course map charts Alzheimer's disease progression. Sci Rep. 2021; 11: 16. 33850174 PMC8044144
  112. [122]Kuhnel L, Bouteloup V, Lespinasse J, et al. Personalized prediction of progression in pre‐dementia patients based on individual biomarker profile: a development and validation study. Alzheimers Dement. 2021; 17: 1938‐ 1949. 34581496
  113. [123]Betthauser TJ, Bilgel M, Koscik RL, et al. Multi‐method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain. 2022; 145: 4065‐ 4079. 35856240 PMC9679170
  114. [124]Powell F, Tosun D, Raj A, Initiative AsDN. Network‐constrained technique to characterize pathology progression rate in Alzheimer's disease. Brain Commun. 2021; 3: fcab144. 34704025 PMC8376686
  115. [125]Raj A, LoCastro E, Kuceyeski A, Tosun D, Relkin N, Weiner M. Network diffusion model of progression predicts longitudinal patterns of atrophy and metabolism in Alzheimer's disease. Cell Rep. 2015; 10: 359‐ 369. 25600871 PMC5747552
  116. [127]Sato K, Mano T, Ihara R, et al. Cohort‐specific optimization of models predicting preclinical Alzheimer's disease, to enhance screening performance in the middle of preclinical Alzheimer's disease clinical studies. JPAD‐J Prev Alzheimers Dis. 2021; 8: 503‐ 512. 34585226
  117. [128]Tosun D, Veitch D, Aisen P, et al. Detection of β‐amyloid positivity in Alzheimer's disease neuroimaging initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun. 2021; 3: fcab008. 33842885 PMC8023542
  118. [129]Wu J, Dong Q, Gui J, et al. Predicting brain amyloid using multivariate morphometry statistics, sparse coding, and correntropy: validation in 1,101 individuals from the ADNI and OASIS databases. Front Neurosci. 2021; 15: 669595. 34421510 PMC8377280
  119. [130]Giorgio J, Jagust WJ, Baker S, Landau SM, Tino P, Kourtzi Z. A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation. Nat Commun. 2022; 13: 1887. 35393421 PMC8989879
  120. [131]Yang F, Chowdhury SR, Jacobs HIL, et al. Longitudinal predictive modeling of tau progression along the structural connectome. Neuroimage. 2021; 237: 118126. 33957234 PMC8260445
  121. [132]Sun YQ, Wang M, Zhao YX, et al. A Pathway‐specific polygenic risk score is associated with tau pathology and cognitive decline. J Alzheimers Dis. 2022; 85: 1745‐ 1754. 34958026
  122. [133]Rubinski A, Frerich S, Malik R, et al. Polygenic effect on tau pathology progression in Alzheimer's disease. Ann Neurol. 2023; 93:819‐829. 36571564
  123. [134]Kim J, Park Y, Park S, et al. Prediction of tau accumulation in prodromal Alzheimer's disease using an ensemble machine learning approach. Sci Rep. 2021; 11: 5706. 33707488 PMC7970986
  124. [136]Gonneaud J, Baria AT, Pichet Binette A, et al. Accelerated functional brain aging in pre‐clinical familial Alzheimer's disease. Nat Commun. 2021; 12: 5346. 34504080 PMC8429427
  125. [137]Huang W, Li X, Li H, et al. Accelerated brain aging in amnestic mild cognitive impairment: relationships with individual cognitive decline, risk factors for Alzheimer disease, and clinical progression. Radiol Artif Intell. 2021; 3: e200171. 34617021 PMC8489444
  126. [138]Taylor A, Zhang F, Niu X, et al. Investigating the temporal pattern of neuroimaging‐based brain age estimation as a biomarker for Alzheimer's disease related neurodegeneration. Neuroimage. 2022; 263: 119621. 36089183 PMC9995621
  127. [139]Milicic L, Vacher M, Porter T, et al. Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. Geroscience. 2022; 44: 1807‐ 1823. 35445885 PMC9213584
  128. [140]Sugden K, Caspi A, Elliott ML, et al. Association of pace of aging measured by blood‐based DNA methylation with age‐related cognitive impairment and dementia. Neurology. 2022; 99: e1402‐ e1413. 35794023 PMC9576288
  129. [141]Dong A, Zhang G, Liu J, Wei Z. Latent feature representation learning for Alzheimer's disease classification. Comput Biol Med. 2022; 150: 106116. 36215848
  130. [142]Kim BH, Vasanthakumar A, Li QS, et al. Integrative analysis of DNA methylation and gene expression identifies genes associated with biological aging in Alzheimer's disease. Alzheimers Dement. 2022; 14: e12354. PMC9489162 36187194
  131. [143]Wesenhagen KE, Gobom J, Bos I, et al. Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition. Alzheimers Dement. 2022; 14: e12286. PMC9074716 35571963
  132. [144]Adewale Q, Khan AF, Carbonell F, Iturria‐Medina Y. Integrated transcriptomic and neuroimaging brain model decodes biological mechanisms in aging and Alzheimer's disease. eLife. 2021; 10: e62589. 34002691 PMC8131100
  133. [145]Engvig A, Maglanoc LA, Doan NT, Westlye LT, Alzheimer's Disease Neuroimaging I. Data‐driven health deficit assessment improves a frailty index's prediction of current cognitive status and future conversion to dementia: results from ADNI. Geroscience. 2023; 45: 591‐ 611. 36260263 PMC9886733
  134. [147]Morris JC, Weiner M, Xiong C, et al. Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology. Brain. 2022; 145: 3594‐ 3607. 35580594 PMC9989348
  135. [148]Guo T, Korman D, Baker SL, Landau SM, Jagust WJ, Alzheimer's Disease Neuroimaging I. Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology. Biol Psychiatry. 2021; 89: 786‐ 794. 32919611 PMC9682985
  136. [149]Kim CM, Montal V, Diez I, Orwig W, Alzheimer's Disease Neuroimaging I. Network interdigitations of Tau and amyloid‐beta deposits define cognitive levels in aging. Hum Brain Mapp. 2021; 42: 2990‐ 3004. 33955621 PMC8193537
  137. [150]Golriz Khatami S, Salimi Y, Hofmann‐Apitius M, et al. Comparison and aggregation of event sequences across ten cohorts to describe the consensus biomarker evolution in Alzheimer's disease. Alzheimers Res Ther. 2022; 14: 55. [Correction added on September 21, 2023, after first online publication: First author name has been corrected for reference 150.] 35443691 PMC9020023
  138. [151]Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12: 207‐ 216. 23332364 PMC3622225
  139. [152]Insel PS, Donohue MC, Berron D, Hansson O, Mattsson‐Carlgren N. Time between milestone events in the Alzheimer's disease amyloid cascade. Neuroimage. 2021; 227: 117676. 33359337
  140. [153]Jagust WJ, Landau SM, Alzheimer's Disease Neuroimaging I. Temporal dynamics of beta‐amyloid accumulation in aging and Alzheimer disease. Neurology. 2021; 96: e1347‐ e1357. 33408147 PMC8055327
  141. [154]Tosun D, Demir Z, Veitch DP, et al. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimers Dement. 2022; 18: 1370‐ 1382. 34647694 PMC9014819
  142. [155]Damotte V, van der Lee SJ, Chouraki V, et al. Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome‐wide association study in over 12,000 non‐demented participants. Alzheimers Dement. 2021; 17: 1663‐ 1674. 34002480 PMC8597077
  143. [158]Xicota L, Gyorgy B, Grenier‐Boley B, et al. Association of APOE‐Independent Alzheimer disease polygenic risk score with brain amyloid deposition in asymptomatic older adults. Neurology. 2022; 99: e462‐ e475. 35606148 PMC9421597
  144. [159]Wang R, Chopra N, Nho K, et al. Human microRNA (miR‐20b‐5p) modulates Alzheimer's disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer's biomarkers. Mol Psychiatry. 2022; 27: 1256‐ 1273. 35087196 PMC9054681
  145. [160]Xiong W, Cai J, Li R, Wen C, Tan H, Database AsDNI. Rare variant analysis and molecular dynamics simulation in Alzheimer's disease identifies exonic variants in FLG. Genes. 2022; 13: 838. 35627223 PMC9141140
  146. [161]Femminella GD, Harold D, Scott J, Williams J, Edison P, Alzheimer's Disease Neuroimaging I. The differential influence of immune, endocytotic, and lipid metabolism genes on amyloid deposition and neurodegeneration in subjects at risk of Alzheimer's disease. J Alzheimers Dis. 2021; 79: 127‐ 139. 33216025
  147. [162]Mullins R, Kapogiannis D. Alzheimer's disease‐related genes identified by linking spatial patterns of pathology and gene expression. Front Neurosci. 2022; 16: 908650. 35774552 PMC9237461
  148. [163]Pyun JM, Park YH, Hodges A, et al. Immunity gene IFITM3 variant: Relation to cognition and Alzheimer's disease pathology. Alzheimers Dement (Amst). 2022; 14: e12317. 35769874 PMC9212215
  149. [164]Kamagata K, Andica C, Takabayashi K, et al. Association of MRI indices of glymphatic system with amyloid deposition and cognition in mild cognitive impairment and Alzheimer disease. Neurology. 2022; 99: e2648‐ e2660. 36123122 PMC9757870
  150. [165]Chandra A, Farrell C, Wilson H, et al. Aquaporin‐4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum. Neurobiol Aging. 2021; 97: 1‐ 9. 33068891
  151. [166]Zeng Q, Li K, Luo X, et al. The association of enlarged perivascular space with microglia‐related inflammation and Alzheimer's pathology in cognitively normal elderly. Neurobiol Dis. 2022; 170: 105755. 35577066
  152. [167]Shi X, Zhou N, Sun B, et al. Perivascular space predicts brain hypometabolism of individuals with underlying amyloid pathology. J Alzheimers Dis. 2022; 90: 1329‐ 1337. 36245373
  153. [168]Wang ML, Yu MM, Wei XE, Li WB, Li YH, Alzheimer's Dis N. Association of enlarged perivascular spaces with A beta and tau deposition in cognitively normal older population. Neurobiol Aging. 2021; 100: 32‐ 38. 33477009
  154. [169]Wang ML, Zou QQ, Sun Z, et al. Associations of MRI‐visible perivascular spaces with longitudinal cognitive decline across the Alzheimer's disease spectrum. Alzheimers Res Ther. 2022; 14: 185. 36514127 PMC9746143
  155. [170]Han F, Chen J, Belkin‐Rosen A, et al. Reduced coupling between cerebrospinal fluid flow and global brain activity is linked to Alzheimer disease‐related pathology. PLoS Biol. 2021; 19: e3001233. 34061820 PMC8168893
  156. [171]Xu W, Tan CC, Zou JJ, Cao XP, Tan L, Alzheimers Disease Neuroimaging I. Insomnia moderates the relationship between amyloid‐beta and cognitive decline in late‐life adults without dementia. J Alzheimers Dis. 2021; 81: 1701‐ 1710. 33967043
  157. [172]Kim H, Levine A, Cohen D, et al. The role of amyloid, tau, and apoe genotype on the relationship between informant‐reported sleep disturbance and Alzheimer's disease risks. J Alzheimers Dis. 2022; 87: 1567‐ 1580. 35491776 PMC9644449
  158. [173]Bubu OM, Umasabor‐Bubu OQ, Turner AD, et al. Self‐reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time‐dependent progression. Alzheimers Dement. 2021; 17: 226‐ 245. PMC8026765 33090679
  159. [174]Park YH, Pyun JM, Hodges A, et al. Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid‐beta deposition in Alzheimer's disease. Alzheimers Res Ther. 2021; 13: 10. 34732252 PMC8567578
  160. [175]Li TR, Lyu DY, Liu FQ, Alzheimer's Disease Neuroimaging I. Cerebrospinal fluid sTREM2 in Alzheimer's disease Is associated with both amyloid and tau pathologies but not with cognitive status. J Alzheimers Dis. 2022; 90: 1123‐ 1138. 36213998
  161. [176]Chen YH, Lin RR, Huang HF, Xue YY, Tao QQ. Microglial activation, tau pathology, and neurodegeneration biomarkers predict longitudinal cognitive decline in Alzheimer's disease continuum. Front Aging Neurosci. 2022; 14: 848180. 35847667 PMC9280990
  162. [177]Leng F, Zhan Z, Sun Y, et al. Cerebrospinal fluid strem2 has paradoxical association with brain structural damage rate in early‐ and late‐stage Alzheimer's disease. J Alzheimers Dis. 2022; 88: 117‐ 126. 35491791
  163. [178]Pillai JA, Khrestian M, Bena J, Leverenz JB, Bekris LM. Temporal ordering of inflammatory analytes sTNFR2 and sTREM2 in relation to Alzheimer's disease biomarkers and clinical outcomes. Front Aging Neurosci. 2021; 13: 676744. 34276339 PMC8279003
  164. [179]Wang ZB, Ma YH, Sun Y, Tan L, Wang HF, Yu JT. Interleukin‐3 is associated with sTREM2 and mediates the correlation between amyloid‐β and tau pathology in Alzheimer's disease. J Neuroinflammation. 2022; 19: 316. 36578067 PMC9798566
  165. [180]Shi X, Zhong X, Zhou H, Zhou N, Hu Y, Ning Y. The association between cerebrospinal ferritin and soluble triggering receptor expressed on myeloid cells 2 along Alzheimer's continuum. Front Neurol. 2022; 13: 961842. 36408515 PMC9669339
  166. [181]Pan R, Luo S, Huang Q, et al. The associations of cerebrospinal fluid ferritin with neurodegeneration and neuroinflammation along the Alzheimer's disease continuum. J Alzheimers Dis. 2022; 88: 1115‐ 1125. 35754266
  167. [182]Ayton S, Janelidze S, Kalinowski P, et al. CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers. J Neurol Neurosurg Psychiatry. 2023; 94: 211‐ 219. 36357168 PMC9992756
  168. [183]Contreras JA, Aslanyan V, Albrecht DS, Mack WJ, Pa J. Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia. Alzheimers Dement. 2022; 14: e12346. PMC9484791 36187197
  169. [184]Xu W, Tan CC, Cao XP, Tan L, Alzheimer's Disease Neuroimaging I. Neuroinflammation modulates the association of PGRN with cerebral amyloid‐beta burden. Neurobiol Aging. 2021; 103: 52‐ 59. 33813350
  170. [185]Bernier RA, Banks SJ, Panizzon MS, et al. The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer's disease spectrum. Alzheimers Dement. 2022; 14: e12284. PMC8973901 35386474
  171. [186]Clark AL, Weigand AJ, Thomas KR, et al. Elevated inflammatory markers and arterial stiffening exacerbate tau but not amyloid pathology in older adults with mild cognitive impairment. J Alzheimers Dis. 2021; 80: 1451‐ 1463. 33682714 PMC9052932
  172. [187]Wu Q, Kong W, Wang S. Peripheral blood biomarkers CXCL12 and TNFRSF13C associate with cerebrospinal fluid biomarkers and infiltrating immune cells in Alzheimer disease. J Mol Neurosci. 2021; 71: 1485‐ 1494. 33687622
  173. [188]Li Y, Huang X, Fowler C, et al. Identification of leukocyte surface P2×7 as a biomarker associated with Alzheimer's disease. Int J Mol Sci. 2022; 23: 7687. 35887215 PMC9322488
  174. [189]Huang J, Tao Q, Ang TFA, et al. The impact of increasing levels of blood C‐reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer's disease. Transl Psychiatry. 2022; 12: 523. 36550123 PMC9780312
  175. [190]Tao Q, Alvin Ang TF, Akhter‐Khan SC, et al. Impact of C‐reactive protein on cognition and Alzheimer disease biomarkers in homozygous apolipoprotein E varepsilon4 carriers. Neurology. 2021; 97: e1243‐ e1252. 34266923 PMC8480484
  176. [191]Patel D, Zhang X, Farrell JJ, Lunetta KL, Farrer LA. Set‐based rare variant expression quantitative trait loci in blood and brain from Alzheimer disease study participants. Genes (Basel). 2021; 12: 419. 33804025 PMC7999141
  177. [192]Neumann A, Kucukali F, Bos I, et al. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Mol Psychiatry. 2022; 27: 1990‐ 1999. 35173266 PMC9126805
  178. [193]Horgusluoglu E, Neff R, Song WM, et al. Integrative metabolomics‐genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. Alzheimers Dement. 2022; 18: 1260‐ 1278. 34757660 PMC9085975
  179. [194]Novotny BC, Fernandez MV, Wang C, et al. Metabolomic and lipidomic signatures in autosomal dominant and late‐onset Alzheimer's disease brains. Alzheimers Dement. 2023; 19:1785‐1799. PMC10106526 36251323
  180. [195]Nho K, Kueider‐Paisley A, Arnold M, et al. Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. Brain Commun. 2021; 3: fcab139. 34396103 PMC8361396
  181. [196]Shanks HR, Onuska KM, Barupal DK, Schmitz TW. Initiative AsDN, consortium AsDM. Serum unsaturated phosphatidylcholines predict longitudinal basal forebrain degeneration in Alzheimer's disease. Brain Commun. 2022; 4: fcac318. 37064049 PMC10103184
  182. [197]Sakr F, Dyrba M, Brauer A, Teipel S, Alzheimer's Disease Neuroimaging I. Association of lipidomics signatures in blood with clinical progression in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis. 2022; 85: 1115‐ 1127. 34897082
  183. [198]Baloni P, Arnold M, Buitrago L, et al. Multi‐Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. Commun Biol. 2022; 5: 13. 36209301 PMC9547905
  184. [199]Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. Alzheimers Dement. 2023; 19: 333‐ 342. 35522844
  185. [200]Paliwal D, McInerney TW, Pa J, et al. Mitochondrial pathway polygenic risk scores are associated with Alzheimer's disease. Neurobiol Aging. 2021; 108: 213‐ 222. 34521561
  186. [201]Xu X, Wang H, Bennett DA, Zhang QY, Wang G, Zhang HY. Systems genetic identification of mitochondrion‐associated Alzheimer's disease genes and implications for disease risk prediction. Biomedicines. 2022; 10: 20. PMC9330299 35892682
  187. [202]Stage E, Risacher SL, Lane KA, et al. Association of the top 20 Alzheimer's disease risk genes with [(18)F]flortaucipir PET. Alzheimers Dement (Amst). 2022; 14: e12308. 35592828 PMC9092485
  188. [203]Franzmeier N, Ossenkoppele R, Brendel M, et al. The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Abeta‐associated tau accumulation and cognitive decline. Alzheimers Dement. 2022; 18: 103‐ 115. 34060233
  189. [204]Pelgrim TAD, Beran M, Twait EL, Geerlings MI, Vonk JMJ. Cross‐sectional associations of tau protein biomarkers with semantic and episodic memory in older adults without dementia: a systematic review and meta‐analysis. Ageing Res Rev. 2021; 71: 101449. 34400308
  190. [205]Guo Y, Yang YX, Zhang YR, et al. Genome‐wide association study of brain tau deposition as measured by (18)F‐flortaucipir positron emission tomography imaging. Neurobiol Aging. 2022; 120: 128‐ 136. 36195041
  191. [206]Belloy ME, Eger SJ, Le Guen Y, et al. KL*VS heterozygosity reduces brain amyloid in asymptomatic at‐risk APOE*4 carriers. Neurobiol Aging. 2021; 101: 123‐ 129. 33610961 PMC8122023
  192. [207]Neitzel J, Franzmeier N, Rubinski A, et al. KL‐VS heterozygosity is associated with lower amyloid‐dependent tau accumulation and memory impairment in Alzheimer's disease. Nat Commun. 2021; 12: 3825. 34158479 PMC8219708
  193. [208]Picard C, Nilsson N, Labonté A, et al. Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. Alzheimers Dement. 2022; 18: 875‐ 887. 34590423 PMC9293308
  194. [209]Khan AF, Adewale Q, Baumeister TR, et al. Personalized brain models identify neurotransmitter receptor changes in Alzheimer's disease. Brain. 2022; 145: 1785‐ 1804. 34605898 PMC9423713
  195. [210]Qiang Q, Skudder‐Hill L, Toyota T, Wei W, Adachi H. CSF GAP‐43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer's disease. Sci Rep. 2022; 12: 17392. 36253408 PMC9576773
  196. [211]Lan G, Cai Y, Li A, et al. Association of presynaptic loss with Alzheimer's disease and cognitive decline. Ann Neurol. 2022; 92: 1001‐ 1015. 36056679
  197. [212]Ohrfelt A, Benedet AL, Ashton NJ, et al. Association of CSF GAP‐43 with the rate of cognitive decline and progression to dementia in amyloid‐positive individuals. Neurology. 2023; 100: e275‐ e285. 36192174 PMC9869758
  198. [213]Libiger O, Shaw LM, Watson MH, et al. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimers Dement. 2021; 17: 1976‐ 1987. 33984181 PMC9222372
  199. [214]Hong S, Dobricic V, Ohlei O, et al. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimers Dement. 2021; 17: 1628‐ 1640. 33991015
  200. [215]Prokopenko D, Morgan SL, Mullin K, et al. Whole‐genome sequencing reveals new Alzheimer's disease‐associated rare variants in loci related to synaptic function and neuronal development. Alzheimers Dement. 2021; 17: 1509‐ 1527. 33797837 PMC8519060

200 of 302 shown

Cited by

Sorted by citations

Authors
Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., Morris, J. C., Nho, K. T., Nosheny, R., Okonkwo, O., Perrin, R. J., Petersen, R. C., Rivera Mindt, M., Saykin, A., Shaw, L. M., Toga, A. W., Tosun, D., & Initiative, F. T. A. D. N.
Affiliations
  • San Francisco VA Medical Center (US)
  • University of Southern California (US)
  • Department of Veterans Affairs Medical Center Northern California Institute for Research and Education (NCIRE) San Francisco California USA
  • University of California, Davis (US)
  • Broad Institute (US)
  • Mayo Clinic (US)
  • University of California, Berkeley (US)
  • Washington University in St. Louis (US)
  • Indiana University Indianapolis (US)
  • University of Wisconsin–Madison (US)
  • Department of Psychology Latin American and Latino Studies Institute African and African American Studies Fordham University New York New York USA
  • University of Pennsylvania (US)
Corresponding author
Weiner, Michael W.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2023-09-12
Volume
20
Issue
1
Pages
652-694
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1002/alz.13449
PMC
PMC10841343
OpenAlex
W4386624665
Cited by
113
References
18
Citations by year
2026: 48 · 2025: 39 · 2024: 22 · 2023: 4
FWCI
5.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
Funders
  • National Institutes of Health (U19 ‐AG 024904)
  • National Institute on Aging
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, Alzheimer's Disease Neuroimaging Initiative
MeSH terms
Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Neuroimaging, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review